NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that it has commenced an investigation of Derma Sciences, Inc. (“Derma Sciences” or the “Company”) (NASDAQ:DSCI) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On November 12, 2015, Derma Sciences announced the termination of its Phase 3 clinical trials with aclerastide for diabetic foot ulcer healing after a data monitoring committee issued a futility determination. Upon this news, shares of Derma Sciences were down 27.59% on intraday trading. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.